<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="iso-abbrev">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="publisher-id">ECAM</journal-id><journal-title-group><journal-title>Evidence-based Complementary and Alternative Medicine : eCAM</journal-title></journal-title-group><issn pub-type="ppub">1741-427X</issn><issn pub-type="epub">1741-4288</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21869902</article-id><article-id pub-id-type="pmc">3159308</article-id><article-id pub-id-type="doi">10.1155/2012/892182</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>
<italic>Uncaria tomentosa</italic> for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Farias</surname><given-names>I. L. G.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1, 2</sup>
</xref><xref ref-type="aff" rid="I2">
</xref></contrib><contrib contrib-type="author"><name><surname>Ara&#x000fa;jo</surname><given-names>M. C. S.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1, 2</sup>
</xref><xref ref-type="aff" rid="I2">
</xref></contrib><contrib contrib-type="author"><name><surname>Farias</surname><given-names>J. G.</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rossato</surname><given-names>L. V.</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Elsenbach</surname><given-names>L. I.</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dalmora</surname><given-names>S. L.</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Flores</surname><given-names>N. M. P.</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Durigon</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cruz</surname><given-names>I. B. M.</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Morsch</surname><given-names>V. M.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Schetinger</surname><given-names>M. R. C.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Departamento de Qu&#x000ed;mica, Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil</aff><aff id="I2"><sup>2</sup>Hospital Universit&#x000e1;rio de Santa Maria, Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil</aff><aff id="I3"><sup>3</sup>Departamento de Biologia, Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil</aff><aff id="I4"><sup>4</sup>Departamento de Farm&#x000e1;cia Industrial, Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil</aff><aff id="I5"><sup>5</sup>Departamento de Morfologia, Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil</aff><author-notes><corresp id="cor1">*M. R. C. Schetinger: <email>mariachitolina@gmail.com</email></corresp><fn fn-type="other"><p>Academic Editor: Angelo Antonio Izzo</p></fn></author-notes><pub-date pub-type="ppub"><year>2012</year></pub-date><pub-date pub-type="epub"><day>21</day><month>8</month><year>2011</year></pub-date><volume>2012</volume><elocation-id>892182</elocation-id><history><date date-type="received"><day>26</day><month>3</month><year>2011</year></date><date date-type="rev-recd"><day>18</day><month>6</month><year>2011</year></date><date date-type="accepted"><day>23</day><month>6</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012 I. L. G. Farias et al.</copyright-statement><copyright-year>2012</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>To evaluate the effectiveness of <italic>Uncaria tomentosa</italic> in minimizing the side effects of chemotherapy and improving the antioxidant status of colorectal cancer (CRC) patients, a randomized clinical trial was conducted. Patients (43) undergoing adjuvant/palliative chemotherapy with 5-Fluorouracil/leucovorin + oxaliplatin (FOLFOX4) were split into two groups: the UT group received chemotherapy plus 300&#x02009;mg of <italic>Uncaria tomentosa</italic> daily and the C group received only FOLFOX4 and served as a control. Blood samples were collected before each of the 6 cycles of chemotherapy, and hemograms, oxidative stress, enzymes antioxidants, immunologic parameters, and adverse events were analyzed. The use of 300&#x02009;mg of <italic>Uncaria tomentosa</italic> daily during 6 cycles of FOLFOX4 did not change the analyzed parameters, and no toxic effects were observed.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>After histological diagnosis of colorectal cancer, the treatment of advanced stages of cancer involves adjuvant or palliative chemotherapy.One common treatment plan includes the application of 5-fluoruracil (5FU)/leucovorin and oxaliplatin (FOLFOX4) [<xref rid="B1" ref-type="bibr">1</xref>]. However, side effects from this treatment include severe neutropenia (grade 3 or 4 according to Common Toxicity Criteria of the National Cancer Institute) in 41.1% of patients [<xref rid="B1" ref-type="bibr">1</xref>]. Besides the cytotoxic effect of the chemotherapy, the cause of the neutropenia may be related to oxidative stress, because high H<sub>2</sub>O<sub>2</sub> levels may negatively influence the proliferation and differentiation of myeloid precursors [<xref rid="B2" ref-type="bibr">2</xref>]. There is a well-documented relationship between oxidative stress and colorectal cancer. Oxidative stress may result in both DNA damage [<xref rid="B3" ref-type="bibr">3</xref>] and the expansion of neoplastic cells, because tumoral metabolic adaptations generate high level of reactive oxygen species (ROS) [<xref rid="B4" ref-type="bibr">4</xref>]. Additionally, chemotherapeutic cancer treatments increase oxidative stress levels [<xref rid="B5" ref-type="bibr">5</xref>], resulting in high levels of reactive oxygen species (ROS) and damage to the lipids of the cytoplasmic membrane, cellular proteins, and DNA [<xref rid="B2" ref-type="bibr">2</xref>].</p><p>The immune status of patients, particularly CD8<sup>+</sup> and CD4<sup>+</sup> T cells (T<sub>regs</sub>) levels, shows a correlation with survival. The CD4<sup>+</sup>/CD8<sup>+</sup> ratio of the tumor infiltrating lymphocytes is significantly associated with colorectal cancer prognosis [<xref rid="B6" ref-type="bibr">6</xref>]. Treatment with 5FU increases IFN-<italic>&#x003b3;</italic> production through the action of tumor-specific CD8<sup>+</sup> T cells that infiltrate the tumor, and it promotes T cell-dependent antitumor responses <italic>in vivo</italic> [<xref rid="B7" ref-type="bibr">7</xref>]. Again, there is an interaction between the immune response and oxidative stress. Exposure to reactive oxygen species (ROS) produced by activated granulocytes and macrophages in the context of malignant disorders causes dysfunction of T-cells and NK cells [<xref rid="B8" ref-type="bibr">8</xref>]. High levels of superoxide dismutase (SOD&#x02014;an antioxidant enzyme) contribute to tumor cell resistance and therapy insensitivity and are correlated with poor outcome [<xref rid="B9" ref-type="bibr">9</xref>].</p><p>For these reasons, it is important to search for complementary treatments, including phytotherapic plants, that minimize the neutropenia associated with colon cancer chemotherapy. <italic>Uncaria tomentosa </italic>(<italic>Ut</italic>, Cat's claw) has antioxidant properties [<xref rid="B10" ref-type="bibr">10</xref>] and can stimulate DNA repair [<xref rid="B11" ref-type="bibr">11</xref>] and myelopoiesis [<xref rid="B12" ref-type="bibr">12</xref>]. Eberlin et al. [<xref rid="B12" ref-type="bibr">12</xref>] showed that <italic>Ut</italic> extract promotes proliferation of myeloid precursors through the increase in serum colony stimulating growth factors (CSFs). Other preclinical experiments have demonstrated the positive effect of aqueous <italic>Ut</italic> extract on leukocyte counts over a period of eight weeks in healthy animals [<xref rid="B13" ref-type="bibr">13</xref>] and after ten days of doxorubicin-induced neutropenia [<xref rid="B14" ref-type="bibr">14</xref>]. Given these characteristics, <italic>Ut</italic> could minimize the undesirable effects of chemotherapy and might improve the balance between stress and antioxidants in cancer patients. This clinical study aimed to evaluate the effect of coadjuvant treatment with <italic>Ut</italic> compared with conventional chemotherapy for colorectal cancer. The investigation evaluated the effect of <italic>Ut</italic> on oxidative stress and its consequences in relation to neutropenia, other hematological parameters, immune system, safety, and side effects.</p></sec><sec id="sec2"><title>2. Methods</title><sec sec-type="subsection" id="sec2.1"><title>2.1. Design and Patients</title><p>We performed a randomized interventional study of colorectal cancer patients who were submitted to chemotherapy treatment. </p><p>The study was carried out with 43 patients (26 female, 17 male) who had undergone complete resection of their colorectal cancer, which was of histologically scored as stage IIB, III, or IV, and who were going to begin adjuvant/palliative chemotherapy with FOLFOX4 at the <italic>Hospital Universit&#x000e1;rio de Santa Maria</italic>, Brazil. </p><p>Patients were randomly grouped into two groups, according to the date of treatment start as follows: the first patient who agreed participating in the study was included into UT group, the second into the C group, and successively until the end. The UT group was treated with FOLFOX4 plus <italic>Ut</italic>, and the control group (C) received only FOLFOX4. Patients remained on study during 6 chemotherapies cycles, of 15 days each. The doses of medication in UT group were as follows: Oxaliplatin, 85&#x02009;mg/m&#x000b2; on day1; 5FU, 1&#x02009;g/m&#x000b2; on days 1 and 2; Leucovorin, 200&#x02009;mg/m&#x000b2; on days 1 and 2; and <italic>Ut</italic> (Unha de Gato Herbarium), 3 tablets daily from day 3 to day 15. The dose of <italic>Ut </italic>is similar to that used in previous study, using 250&#x02013;350&#x02009;mg C-MED-100, an aqueous extracts of <italic>Ut</italic> [<xref rid="B11" ref-type="bibr">11</xref>]. No changes in food intake pattern had occurred during the supplementation.</p><p>
The calculation for estimating the sample size required for a randomized clinical trial was according to Greenberg et al. [<xref rid="B15" ref-type="bibr">15</xref>], with constant level of significance (<italic>&#x003b1;</italic>) of 5%, and statistical power of 90% (<italic>&#x003b2;</italic> 10%), using as a reference the study of Sheng et al. [<xref rid="B13" ref-type="bibr">13</xref>].</p><p>The Human Ethics Committee of the <italic>Universidade Federal de Santa Maria</italic> approved this study, and informed consent was obtained from all participants (protocol n. 0169.0.243.000-07).</p></sec><sec sec-type="subsection" id="sec2.2"><title>2.2. Materials</title><p>Each tablet of Unha de Gato Herbarium contained 100&#x02009;mg dry <italic>Ut</italic> extract. Biological materials used in the tablets were derived from plants in their natural habitat. The <italic>Ut</italic> extract was prepared by ultra-turrax extraction (Biotron, Kinematica AG) from ground bark (Centroflora) using 70% ethanol (Dipalcool). The HPLC analysis of <italic>Ut </italic>dry extract presents the content of 2.57% pentacyclic oxindole alkaloids (POAs), which were calculated with reference to external calibration curves of mitraphylline. The analysis of extract showed absence of tetracyclic oxindole alkaloids in the sample, allowing its use for therapeutic and research purposes in accordance with U.S. Pharmacopeia.</p></sec><sec sec-type="subsection" id="sec2.3"><title>2.3. Sample Collection</title><p>Blood was collected in citrated, EDTA, heparin, and without anticoagulant Vacutainer tubes, before chemotherapy and after each of the 6 cycles. CAT and SOD activities were determined using whole blood diluted in a 1&#x02009;:&#x02009;20 saline solution.</p></sec><sec sec-type="subsection" id="sec2.4"><title>2.4. Biochemical Parameters</title><p>A COBAS INTEGRA system was used for the quantitative determination of the chemical constituents of the blood, and data were acquired using a COBAS INTEGRA 400 plus apparatus (USA).</p></sec><sec sec-type="subsection" id="sec2.5"><title>2.5. Carbonylation of Serum Protein</title><p>The carbonylation of serum proteins was determined through a modification of the Levine method [<xref rid="B16" ref-type="bibr">16</xref>].</p></sec><sec sec-type="subsection" id="sec2.6"><title>2.6. Determination of Lipid Peroxidation</title><p>Lipid peroxidation was estimated by measuring TBARS in plasma samples according to a modification of the method of Jentzsch et al. [<xref rid="B17" ref-type="bibr">17</xref>].</p></sec><sec sec-type="subsection" id="sec2.7"><title>2.7. Catalase (CAT) and Superoxide Dismutase (SOD) Activities</title><p>The determination of CAT activity level was carried out in accordance with a modification of the method of Nelson and Kiesow [<xref rid="B18" ref-type="bibr">18</xref>]. SOD activity was calculated based on the ability to inhibit the reaction of superoxide and adrenaline, as described by McCord and Fridovich [<xref rid="B19" ref-type="bibr">19</xref>].</p></sec><sec sec-type="subsection" id="sec2.8"><title>2.8. Hemograms</title><p>Blood samples were analyzed using a Pentra apparatus (France). The lowest values were confirmed by observation of slides using May Gr&#x000fc;nwald-Giemsa stain and optical microscopy.</p></sec><sec sec-type="subsection" id="sec2.9"><title>2.9. Interleukin 6 (IL-6)</title><p>ELISA assays of IL-6 were carried out according to a previously published method [<xref rid="B20" ref-type="bibr">20</xref>] at room temperature in 96-well microtitre plates (Nunc-Immuno Plate Maxi Sorp), and optical densities (O.D.) at 490&#x02009;nm were determined using a microplate reader (Thermo Scientific Multiskan FC, Vantaa, Finland).</p></sec><sec sec-type="subsection" id="sec2.10"><title>2.10. Single Cell Gel Electrophoresis (Comet Assay)</title><p>Alkaline comet assays were performed as described by Singh et al. [<xref rid="B21" ref-type="bibr">21</xref>]. One hundred cells (50 cells from each of the two replicate slides) were selected and analyzed. The slides were analyzed under blind conditions by at least two different individuals.</p></sec><sec sec-type="subsection" id="sec2.11"><title>2.11. CD3<sup>+</sup>, CD4<sup>+</sup>, and CD8<sup>+</sup> Cells</title><p>Samples were collected in EDTA, and analyses were performed using a three-color fluorescence-activated cell sorter (FACScalibur, Becton Dickinson Biosciences, USA) and Multiset software (Becton Dickinson). FITC-conjugated anti-CD4, PE conjugated anti-CD8 and PerCp conjugated anti-CD3 were used. Immune subpopulations were measured as a percentage of the total number of CD3<sup>+</sup> cells.</p></sec><sec sec-type="subsection" id="sec2.12"><title>2.12. Adverse Events</title><p>The Common Terminology Criteria for Adverse Events (AE) v3.0 (CTCAE) from the National Institutes of Health/National Cancer Institute-EUA [<xref rid="B22" ref-type="bibr">22</xref>] has been used. Grade refers to the severity of the AE. The CTCAE v3.0 employs grades from 1 to 5, with unique clinical descriptions of severity for each AE based on the following general guideline: grade 1, mild AE, grade 2, moderate AE, grade 3, severe AE, grade 4, life-threatening or disabling AE, and grade 5, death related to an AE. The adverse events were judged in terms of clinical symptoms by interview at each chemotherapy cycle with pharmaceutical. Serum clinical chemistry, whole blood analysis, and leukocyte differential counts were also used to monitor the efficacy and toxicity by physicians of the Department of Oncology.</p></sec><sec sec-type="subsection" id="sec2.13"><title>2.13. Statistics</title><p>Data were analyzed using the EpiInfo computer program, version 3.5.1 from the CDC, USA. The data were evaluated using analysis of variance (ANOVA) and <italic>t</italic>-test and were expressed as a mean &#x000b1; SD. When the variances were not homogenous and ANOVA was not appropriate (Bartlett's <italic>P</italic> value &#x0003c; 0.05), Wilcoxon two-sample test was used to evaluate the data. <italic>P</italic> &#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec id="sec3"><title>3. Results</title><p>The general characteristics of colorectal cancer patients included in this study are shown in <xref ref-type="table" rid="tab1">Table 1</xref>. The mean age of the C group was 60.89 years, and the mean age of the UT group was 62.68 years old.</p><p>One aim of the study was to evaluate the neutropenia, thrombocytopenia, and anemia. The hemograms were analyzed each 15 days, and there were no significant differences in hematological parameters (Tables <xref ref-type="table" rid="tab2">2</xref> and <xref ref-type="table" rid="tab3">3</xref>) between the groups for any of the cycles examined. An important reduction in white blood cells (WBCs) count was observed in both groups along the treatment. Unlike what was observed in leukocytes, red blood cells (RBCs) showed recovery of the hypochromic and microcytosis present at baseline. Erythrocyte indices (mean corpuscular hemoglobin-MCH; mean corpuscular volume, MCV) improved in both groups, reaching normal values.</p><p>The generation of ROS may damage all types of biological molecules. Oxidative damages to lipids, proteins, or DNA were evaluated by TBARS levels, protein carbonyl levels, and comet assay, respectively. Antioxidant defense system was measured by activity of antioxidants enzymes catalase and SOD. The <italic>Ut</italic> supplementation did not change oxidative stress values or activity of the antioxidant enzymes. Similarly, the comet assay, a sensitive technique for the detection of DNA damage at the level of the individual eukaryotic cell, demonstrated no differences between groups (<xref ref-type="table" rid="tab4">Table 4</xref>).</p><p>The CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells (absolute count and ratio) used for the evaluation of the immune status of CRC patients were not statistically different following <italic>Ut</italic> supplementation (<xref ref-type="table" rid="tab5">Table 5</xref>) or chemotherapy (before treatment began versus after the sixth FOLFOX4 cycle). The UT and C groups showed differences before chemotherapy in IL-6 levels, but such differences did not change over the course of treatment. Moreover, in the comet assays, IL-6 levels showed large variations between subjects.</p><p>The assessment of adverse events (AEs) related to treatment was conducted by interviewing the patients during each cycle of chemotherapy and through analysis of laboratory tests and observation of abnormal symptoms presented by patients. AEs were classified according to the Common Terminology Criteria for Adverse Events v3.0 (CTCAE v3.0) [<xref rid="B22" ref-type="bibr">22</xref>]. Since there were no differences between groups, data shows that <italic>Ut</italic> supplementation did not alter the occurrence of AEs, related to chemotherapy, neither caused AE. The most frequently observed AE in both groups were fatigue, nausea, and a decrease in hematological parameters (Tables <xref ref-type="table" rid="tab6">6</xref> and <xref ref-type="table" rid="tab7">7</xref>). An important reduction in neutrophils (grade 3 or 4) occurred in 25.4% of patients. Toxicity of the <italic>Ut</italic> was also evaluated using liver, kidney, metabolic, and constitutive parameters. Treatment with <italic>Ut</italic> did not alter liver function, defined as elevation of liver enzymes (alanine aminotransferase-ALT, aspartate aminotransferase-AST, <italic>&#x003b3;</italic> glutamyl transpeptidase-GGT), and bilirubin levels, and kidney function is evaluated by dosage of urea, metabolic parameters (albumin levels and glycemia), and constitutive parameters (weight loss) (data not shown). There was a small difference in creatinine levels between groups before treatment (UT = 74.25&#x02009;<italic>&#x003bc;</italic>mol/L, C = 68.95&#x02009;<italic>&#x003bc;</italic>mol/L), which remained at the sixth cycle of treatment (UT = 76.90&#x02009;<italic>&#x003bc;</italic>mol/L, C = 60.12&#x02009;<italic>&#x003bc;</italic>mol/L).</p></sec><sec id="sec4"><title>4. Discussion</title><p>Complementary and alternative medicine (CAM) has been used by a large number of cancer patients worldwide. Cultural, socioeconomic, and spiritual differences affect the rate of use. For instance, there are high rates of use in Mexico (97.2%) and China (97%) [<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>], an intermediate rate of use in the USA (63%) [<xref rid="B25" ref-type="bibr">25</xref>], and lower rates of use in Canada (47%) [<xref rid="B26" ref-type="bibr">26</xref>] and Iran (35%) [<xref rid="B27" ref-type="bibr">27</xref>]. The herbal remedy cat's claw is used as CAM by some cancer patients. It is thought to be an anticarcinogen, an immunostimulant, and an antioxidant that can stimulate DNA repair. Despite a theoretical understanding of its mechanism of action, the evidence for its clinical effectiveness is minimal [<xref rid="B28" ref-type="bibr">28</xref>].</p><p>To evaluate the effectiveness of <italic>Ut</italic> in minimizing the main side effects of chemotherapy, a decrease in neutrophil and platelet counts, hemograms were analyzed before each FOLFOX4 cycle (at an interval of 15 days). Treatment with <italic>Ut</italic> was suspended on the days that patients received chemotherapy, because some antineoplastic drugs and CAMs are metabolized through the cytochrome P450 family, and an interaction could alter the metabolism of patients [<xref rid="B28" ref-type="bibr">28</xref>]. Treatment with <italic>Ut</italic> did not improve the WBC, RBC, or platelet counts, because there were no differences between groups (UT versus C). <italic>In vivo</italic> assays in rats undergoing chemotherapy demonstrated that neutrophils recover significantly sooner with <italic>Ut</italic> supplementation [<xref rid="B14" ref-type="bibr">14</xref>]. This effect of <italic>Ut</italic> on WBC is due both to the stimulation of myeloid precursors [<xref rid="B12" ref-type="bibr">12</xref>] and the effect on ROS, which increases survival of lymphocytes [<xref rid="B29" ref-type="bibr">29</xref>] and inhibits myeloid cell differentiation [<xref rid="B2" ref-type="bibr">2</xref>]. We did not find other clinical trials with CRC patients using <italic>Ut</italic>. In a human volunteer study, <italic>Ut</italic> extract was given at 250 or 350&#x02009;mg/day for 8 consecutive weeks to healthy adult. There were no statistically significant differences among the groups in WBC [<xref rid="B11" ref-type="bibr">11</xref>]. Our group conducted a clinical trial of women with breast cancer undergoing chemotherapy treatment who received 300&#x02009;mg of <italic>Ut</italic> daily. In this study, we found significant differences between the group that received <italic>Ut </italic>and the control group; the <italic>Ut</italic> group showed higher neutrophils counts compared with the control group (unpublished data). The differences in the drugs used in the treatment of breast cancer (5-FU, adriamycin, and cyclophosphamide) versus CRC (5-FU and oxaliplatin) have to be considered, as do the differences in time between cycles of chemotherapy (21 versus 15 days). We must also consider the fact that all CRC patients in the present study underwent colectomy, which could interfere with the absorption of <italic>Ut</italic>.</p><p>Many previous studies have clearly shown the potential of the antioxidant <italic>Ut</italic>, and its potent radical scavenger activity was confirmed by several assays including the following: the capacity to reduce the free radical diphenylpycrilhydrazyl (DPPH assay) [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>], the reaction with the superoxide anion, peroxyl [<xref rid="B30" ref-type="bibr">30</xref>], and hydroxyl radicals [<xref rid="B30" ref-type="bibr">30</xref>] as well as with the oxidant species, hydrogen peroxide, and hypochlorous acid [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B32" ref-type="bibr">32</xref>], and the TEAC assay [<xref rid="B10" ref-type="bibr">10</xref>]. The antioxidant activity of <italic>Ut </italic>extracts was further assayed through determination of TBARS production (using rat liver homogenates and sarcoplasmic reticulum membranes) and by the inhibition of free radical-mediated DNA-sugar damage [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B33" ref-type="bibr">33</xref>]. These assays were primarily <italic>in vitro</italic> tests with one <italic>in vivo</italic> test [<xref rid="B31" ref-type="bibr">31</xref>]. Despite this strong evidence, no differences in oxidative stress were found between groups that received or did not receive <italic>Ut</italic>, as assessed by lipid peroxidation (TBARS) and protein carbonyls. In addition, no differences were observed in the antioxidant enzymes SOD or catalase. </p><p>There are close correlations between DNA damage, DNA repair, and immune responses in lymphocytes. DNA damage and mutations may result in a failure of T cells to proliferate and undergo extensive clonal expansion upon antigenic stimulation. Sheng et al. [<xref rid="B11" ref-type="bibr">11</xref>] showed that a water-soluble extract of <italic>Ut</italic> caused a significant decrease in DNA damage and a concomitant increase in DNA repair in volunteers. However, in our study, the comet assay did not demonstrate a significant difference in the group that received <italic>Ut</italic>. <italic>Ut </italic>extract was prepared through an extraction of ground bark with 70% ethanol. This process altered the composition of the extract (oxindole alkaloids) compared with an aqueous extract (like that used by Sheng et al. [<xref rid="B11" ref-type="bibr">11</xref>]). However, more recently, water-soluble cat's claw extract was shown not to contain significant amounts of alkaloids (&#x0003c;0.05%). Yet, it was still shown to be efficacious, because quinic acid is the major active ingredient [<xref rid="B34" ref-type="bibr">34</xref>]. Further study is needed to assess whether differences in the content of the extracts are correlated with the differences in observed results. </p><p>Similar to oxidative stress, <italic>Ut</italic> did not show an effect on the analyzed immunologic parameters, the CD4<sup>+</sup> T cell-CD8<sup>+</sup> T cell count and the IL-6 levels despite the <italic>in vitro</italic> evidence [<xref rid="B35" ref-type="bibr">35</xref>].</p><p>There were no drug-related toxic effects observed for <italic>Ut</italic> extract at a repeated dose of 300&#x02009;mg/day for 12 consecutive weeks (Unha de Gato Herbarium), when judged in terms of clinical symptoms, serum clinical chemistry, whole blood analysis, and leukocyte differential counts. Similar results have been shown in previous studies with volunteers [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B36" ref-type="bibr">36</xref>]. National Center for Complementary and Alternative Medicine (USA) [<xref rid="B37" ref-type="bibr">37</xref>] has reported few side effects from cat's claw at the recommended dosages. Though rare, side effects may include headaches, dizziness, and vomiting.</p><p>Adverse events related to antineoplastic drugs (oxaliplatin and 5FU) are well known [<xref rid="B1" ref-type="bibr">1</xref>] and are similar to those observed in our study.</p></sec><sec id="sec5"><title>5. Conclusion</title><p>
<italic>Ut </italic>at dose 300&#x02009;mg dry extract daily is not effective in reducing the most prevalent adverse events due to treatment with 5FU/Leucovorin and oxaliplatin in patients with advanced CRC. No toxic effects related to <italic>Ut</italic> were observed in the group that received 300&#x02009;mg dry extract daily for 12 weeks. Additional studies are needed to evaluate under which conditions, drugs, or types of cancer <italic>Ut</italic> might have a positive effect on treatment, in decreasing neutropenia and thrombocytopenia, or in improving the immune response.</p></sec><sec id="sec6"><title> Conflict of Interests</title><p>All the authors deny any conflict of interests. This work had a financial support from the government agencies CNPq and CAPES.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank the physicians of the <italic>Servi&#x000e7;o de Hematologia/Oncologia</italic> of the <italic>Hospital Universit&#x000e1;rio de Santa Maria</italic>, Brazil. This work was supported by governmental funds: CNPq and CAPES.</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andr&#x000e9;</surname><given-names>T</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Mounedji-Boudiaf</surname><given-names>L</given-names></name><etal/></person-group><article-title>Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer</article-title><source><italic>New England Journal of Medicine</italic></source><year>2004</year><volume>350</volume><issue>23</issue><fpage>2343</fpage><lpage>2351</lpage><pub-id pub-id-type="pmid">15175436</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusmartsev</surname><given-names>S</given-names></name><name><surname>Gabrilovich</surname><given-names>DI</given-names></name></person-group><article-title>Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species</article-title><source><italic>Journal of Leukocyte Biology</italic></source><year>2003</year><volume>74</volume><issue>2</issue><fpage>186</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">12885935</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mena</surname><given-names>S</given-names></name><name><surname>Ortega</surname><given-names>A</given-names></name><name><surname>Estrela</surname><given-names>JM</given-names></name></person-group><article-title>Oxidative stress in environmental-induced carcinogenesis</article-title><source><italic>Mutation Research</italic></source><year>2009</year><volume>674</volume><issue>1-2</issue><fpage>36</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">18977455</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seyfried</surname><given-names>TN</given-names></name><name><surname>Shelton</surname><given-names>LM</given-names></name></person-group><article-title>Cancer as a metabolic disease</article-title><source><italic>Nutrition and Metabolism</italic></source><year>2010</year><volume>7, article 7</volume></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandre</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Pelicano</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name></person-group><article-title>Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species</article-title><source><italic>Cancer Research</italic></source><year>2007</year><volume>67</volume><issue>8</issue><fpage>3512</fpage><lpage>3517</lpage><pub-id pub-id-type="pmid">17440056</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diederichsen</surname><given-names>ACP</given-names></name><name><surname>Hjelmborg</surname><given-names>JVB</given-names></name><name><surname>Christensen</surname><given-names>PB</given-names></name><name><surname>Zeuthen</surname><given-names>J</given-names></name><name><surname>Fenge</surname><given-names>C</given-names></name></person-group><article-title>Prognostic value of the CD4<sup>+</sup>/CD8<sup>+</sup> ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells</article-title><source><italic>Cancer Immunology, Immunotherapy</italic></source><year>2003</year><volume>52</volume><issue>7</issue><fpage>423</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">12695859</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>J</given-names></name><name><surname>Mignot</surname><given-names>G</given-names></name><name><surname>Chalmin</surname><given-names>F</given-names></name><etal/></person-group><article-title>5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity</article-title><source><italic>Cancer Research</italic></source><year>2010</year><volume>70</volume><issue>8</issue><fpage>3052</fpage><lpage>3061</lpage><pub-id pub-id-type="pmid">20388795</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klemke</surname><given-names>M</given-names></name><name><surname>Samstag</surname><given-names>Y</given-names></name></person-group><article-title>Molecular mechanisms mediating oxidative stress-induced T-cell suppression in cancer</article-title><source><italic>Advances in Enzyme Regulation</italic></source><year>2009</year><volume>49</volume><issue>1</issue><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">19159639</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>AML</given-names></name><name><surname>Bosman</surname><given-names>CB</given-names></name><name><surname>Sier</surname><given-names>CFM</given-names></name><etal/></person-group><article-title>Superoxide dismutases in relation to the overall survival of colorectal cancer patients</article-title><source><italic>British Journal of Cancer</italic></source><year>1998</year><volume>78</volume><issue>8</issue><fpage>1051</fpage><lpage>1057</lpage><pub-id pub-id-type="pmid">9792149</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pilarski</surname><given-names>R</given-names></name><name><surname>Zieli&#x00144;ski</surname><given-names>H</given-names></name><name><surname>Ciesio&#x00142;ka</surname><given-names>D</given-names></name><name><surname>Gulewicz</surname><given-names>K</given-names></name></person-group><article-title>Antioxidant activity of ethanolic and aqueous extracts of <italic>Uncaria tomentosa</italic> (Willd.) DC</article-title><source><italic>Journal of Ethnopharmacology</italic></source><year>2006</year><volume>104</volume><issue>1-2</issue><fpage>18</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">16202551</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Holmgren</surname><given-names>K</given-names></name><name><surname>Pero</surname><given-names>RW</given-names></name></person-group><article-title>DNA repair enhancement of aqueous extracts of <italic>Uncaria tomentosa</italic> in a human volunteer study</article-title><source><italic>Phytomedicine</italic></source><year>2001</year><volume>8</volume><issue>4</issue><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">11515717</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eberlin</surname><given-names>S</given-names></name><name><surname>Dos Santos</surname><given-names>LMB</given-names></name><name><surname>Queiroz</surname><given-names>MLS</given-names></name></person-group><article-title>
<italic>Uncaria tomentosa</italic> extract increases the number of myeloid progenitor cells in the bone marrow of mice infected with Listeria monocytogenes</article-title><source><italic>International Immunopharmacology</italic></source><year>2005</year><volume>5</volume><issue>7-8</issue><fpage>1235</fpage><lpage>1246</lpage><pub-id pub-id-type="pmid">15914328</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>Y</given-names></name><name><surname>Bryngelsson</surname><given-names>C</given-names></name><name><surname>Pero</surname><given-names>RW</given-names></name></person-group><article-title>Enhanced DNA repair, immune function and reduced toxicity of C-MED, a novel aqueous extract from <italic>Uncaria tomentosa</italic>
</article-title><source><italic>Journal of Ethnopharmacology</italic></source><year>2000</year><volume>69</volume><issue>2</issue><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">10687868</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>Y</given-names></name><name><surname>Pero</surname><given-names>RW</given-names></name><name><surname>Wagner</surname><given-names>H</given-names></name></person-group><article-title>Treatment of chemotherapy-induced leukopenia in a rat model with aqueous extract from <italic>Uncaria tomentosa</italic>
</article-title><source><italic>Phytomedicine</italic></source><year>2000</year><volume>7</volume><issue>2</issue><fpage>137</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">10839217</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>RS</given-names></name><name><surname>Daniels</surname><given-names>SR</given-names></name><name><surname>Flanders</surname><given-names>WD</given-names></name><name><surname>Eley</surname><given-names>JW</given-names></name><name><surname>Boring</surname><given-names>JR</given-names></name></person-group><article-title>Appendix A: estimation of sample size requirements for randomized controlled clinical trials</article-title><source><italic>Medical Epidemiology</italic></source><year>2004</year><edition>4th edition</edition><publisher-loc>Columbia, SC, USA</publisher-loc><publisher-name>McGraw-Hill</publisher-name></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Garland</surname><given-names>D</given-names></name><name><surname>Oliver</surname><given-names>CN</given-names></name><etal/></person-group><article-title>Determination of carbonyl content in oxidatively modified proteins</article-title><source><italic>Methods in Enzymology</italic></source><year>1990</year><volume>186</volume><fpage>464</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">1978225</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jentzsch</surname><given-names>AM</given-names></name><name><surname>Bachmann</surname><given-names>H</given-names></name><name><surname>F&#x000fc;rst</surname><given-names>P</given-names></name><name><surname>Biesalski</surname><given-names>HK</given-names></name></person-group><article-title>Improved analysis of malondialdehyde in human body fluids</article-title><source><italic>Free Radical Biology and Medicine</italic></source><year>1996</year><volume>20</volume><issue>2</issue><fpage>251</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">8746446</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>DP</given-names></name><name><surname>Kiesow</surname><given-names>LA</given-names></name></person-group><article-title>Enthalpy of decomposition of hydrogen peroxide by catalase at 25&#x000b0; C (with molar extinction coefficients of H2O2 solutions in the UV)</article-title><source><italic>Analytical Biochemistry</italic></source><year>1972</year><volume>49</volume><issue>2</issue><fpage>474</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">5082943</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCord</surname><given-names>JM</given-names></name><name><surname>Fridovich</surname><given-names>I</given-names></name></person-group><article-title>Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein)</article-title><source><italic>Journal of Biological Chemistry</italic></source><year>1969</year><volume>244</volume><issue>22</issue><fpage>6049</fpage><lpage>6055</lpage><pub-id pub-id-type="pmid">5389100</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taktak</surname><given-names>YS</given-names></name><name><surname>Selkirk</surname><given-names>S</given-names></name><name><surname>Bristow</surname><given-names>AF</given-names></name><etal/></person-group><article-title>Assay of pyrogens by interleukin-6 release from monocytic cell lines</article-title><source><italic>Journal of Pharmacy and Pharmacology</italic></source><year>1991</year><volume>43</volume><issue>8</issue><fpage>578</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">1681074</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>NP</given-names></name><name><surname>McCoy</surname><given-names>MT</given-names></name><name><surname>Tice</surname><given-names>RR</given-names></name><name><surname>Schneider</surname><given-names>EL</given-names></name></person-group><article-title>A simple technique for quantitation of low levels of DNA damage in individual cells</article-title><source><italic>Experimental Cell Research</italic></source><year>1988</year><volume>175</volume><issue>1</issue><fpage>184</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">3345800</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="other"><collab>National Cancer Institute (NCI)</collab><article-title>Common Toxicity Criteria</article-title><comment>2010, <ext-link ext-link-type="uri" xlink:href="http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf">http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf</ext-link></comment></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerson-Cwillich</surname><given-names>R</given-names></name><name><surname>Serrano-Olvera</surname><given-names>A</given-names></name><name><surname>Villalobos-Prieto</surname><given-names>A</given-names></name></person-group><article-title>Complementary and alternative medicine (CAM) in Mexican patients with cancer</article-title><source><italic>Clinical and Translational Oncology</italic></source><year>2006</year><volume>8</volume><issue>3</issue><fpage>200</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">16648120</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Gu</surname><given-names>K</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Shu</surname><given-names>XO</given-names></name></person-group><article-title>The use of complementary and alternative medicine among Chinese women with breast cancer</article-title><source><italic>Journal of Alternative and Complementary Medicine</italic></source><year>2008</year><volume>14</volume><issue>8</issue><fpage>1049</fpage><lpage>1055</lpage><pub-id pub-id-type="pmid">18928393</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sparber</surname><given-names>A</given-names></name><name><surname>Bauer</surname><given-names>L</given-names></name><name><surname>Curt</surname><given-names>G</given-names></name><etal/></person-group><article-title>Use of complementary medicine by adult patients participating in cancer clinical trials</article-title><source><italic>Oncology Nursing Forum</italic></source><year>2000</year><volume>27</volume><issue>4</issue><fpage>623</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">10833691</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helyer</surname><given-names>LK</given-names></name><name><surname>Chin</surname><given-names>S</given-names></name><name><surname>Chui</surname><given-names>BK</given-names></name><etal/></person-group><article-title>The use of complementary and alternative medicines among patients with locally advanced breast cancer&#x02014;a descriptive study</article-title><source><italic>BMC Cancer</italic></source><year>2006</year><volume>6, article 39</volume></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montazeri</surname><given-names>A</given-names></name><name><surname>Sajadian</surname><given-names>A</given-names></name><name><surname>Ebrahimi</surname><given-names>M</given-names></name><name><surname>Haghighat</surname><given-names>S</given-names></name><name><surname>Harirchi</surname><given-names>I</given-names></name></person-group><article-title>Factors predicting the use of complementary and alternative therapies among cancer patients in Iran</article-title><source><italic>European Journal of Cancer Care</italic></source><year>2007</year><volume>16</volume><issue>2</issue><fpage>144</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">17371423</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Werneke</surname><given-names>U</given-names></name><name><surname>Ladenheim</surname><given-names>D</given-names></name><name><surname>McCarthy</surname><given-names>T</given-names></name></person-group><article-title>Complementary alternative medicine for cancer: a review of effectiveness and safety</article-title><source><italic>Cancer Therapy</italic></source><year>2004</year><volume>2</volume><fpage>475</fpage><lpage>500</lpage></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akesson</surname><given-names>C</given-names></name><name><surname>Pero</surname><given-names>RW</given-names></name><name><surname>Ivars</surname><given-names>F</given-names></name></person-group><article-title>C-Med 100, a hot water extract of <italic>Uncaria tomentosa</italic>, prolongs lymphocyte survival in vivo</article-title><source><italic>Phytomedicine</italic></source><year>2003</year><volume>10</volume><issue>1</issue><fpage>23</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">12622460</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gon&#x000e7;alves</surname><given-names>C</given-names></name><name><surname>Dinis</surname><given-names>T</given-names></name><name><surname>Batista</surname><given-names>MT</given-names></name></person-group><article-title>Antioxidant properties of proanthocyanidins of <italic>Uncaria tomentosa</italic> bark decoction: a mechanism for anti-inflammatory activity</article-title><source><italic>Phytochemistry</italic></source><year>2005</year><volume>66</volume><issue>1</issue><fpage>89</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">15649515</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paniagua-P&#x000e9;rez</surname><given-names>R</given-names></name><name><surname>Madrigal-Bujaidar</surname><given-names>E</given-names></name><name><surname>Molina-Jasso</surname><given-names>D</given-names></name><etal/></person-group><article-title>Antigenotoxic, antioxidant and lymphocyte induction effects produced by pteropodine</article-title><source><italic>Basic and Clinical Pharmacology and Toxicology</italic></source><year>2009</year><volume>104</volume><issue>3</issue><fpage>222</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">19175366</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaral</surname><given-names>S</given-names></name><name><surname>Mira</surname><given-names>L</given-names></name><name><surname>Nogueira</surname><given-names>JMF</given-names></name><name><surname>Silva</surname><given-names>APD</given-names></name><name><surname>Helena Flor&#x000ea;ncio</surname><given-names>M</given-names></name></person-group><article-title>Plant extracts with anti-inflammatory properties&#x02014;a new approach for characterization of their bioactive compounds and establishment of structure-antioxidant activity relationships</article-title><source><italic>Bioorganic and Medicinal Chemistry</italic></source><year>2009</year><volume>17</volume><issue>5</issue><fpage>1876</fpage><lpage>1883</lpage><pub-id pub-id-type="pmid">19201196</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desmarchelier</surname><given-names>C</given-names></name><name><surname>Mongelli</surname><given-names>E</given-names></name><name><surname>Coussio</surname><given-names>J</given-names></name><name><surname>Ciccia</surname><given-names>G</given-names></name></person-group><article-title>Evaluation of the <italic>in vitro</italic> antioxidant activity in extracts of <italic>Uncaria tomentosa</italic> (Willd.) DC</article-title><source><italic>Phytotherapy Research</italic></source><year>1997</year><volume>11</volume><issue>3</issue><fpage>254</fpage><lpage>256</lpage></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>Y</given-names></name><name><surname>&#x000c5;kesson</surname><given-names>C</given-names></name><name><surname>Holmgren</surname><given-names>K</given-names></name><name><surname>Bryngelsson</surname><given-names>C</given-names></name><name><surname>Giamapa</surname><given-names>V</given-names></name><name><surname>Pero</surname><given-names>RW</given-names></name></person-group><article-title>An active ingredient of Cat&#x02019;s claw water extracts: identification and efficacy of quinic acid</article-title><source><italic>Journal of Ethnopharmacology</italic></source><year>2005</year><volume>96</volume><issue>3</issue><fpage>577</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">15619581</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemaire</surname><given-names>I</given-names></name><name><surname>Assinewe</surname><given-names>V</given-names></name><name><surname>Cano</surname><given-names>P</given-names></name><name><surname>Awang</surname><given-names>DVC</given-names></name><name><surname>Arnason</surname><given-names>JT</given-names></name></person-group><article-title>Stimulation of interleukin-1 and -6 production in alveolar macrophages by the neotropical liana, <italic>Uncaria tomentosa</italic> (Una de Gato)</article-title><source><italic>Journal of Ethnopharmacology</italic></source><year>1999</year><volume>64</volume><issue>2</issue><fpage>109</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">10197746</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piscoya</surname><given-names>J</given-names></name><name><surname>Rodriguez</surname><given-names>Z</given-names></name><name><surname>Bustamante</surname><given-names>SA</given-names></name><name><surname>Okuhama</surname><given-names>NN</given-names></name><name><surname>Miller</surname><given-names>MJS</given-names></name><name><surname>Sandoval</surname><given-names>M</given-names></name></person-group><article-title>Efficacy and safety of freeze-dried cat&#x02019;s claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis</article-title><source><italic>Inflammation Research</italic></source><year>2001</year><volume>50</volume><issue>9</issue><fpage>442</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">11603848</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="other"><collab>National Center for Complementary and Alternative Medicine, National Institutes of Health</collab><article-title>Herbs at a glance/Cat&#x02019;s Claw</article-title><comment>2011, <ext-link ext-link-type="uri" xlink:href="http://nccam.nih.gov/health/catclaw/">http://nccam.nih.gov/health/catclaw/</ext-link></comment></element-citation></ref></ref-list></back><floats-group><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>General data of the CRC patients in adjuvant/palliative chemotherapy (FOLFOX4) without <italic>Uncaria tomentosa </italic>supply (C group) or receiving 300&#x02009;mg/day of <italic>Uncaria tomentosa</italic> (UT group).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="2" rowspan="1">
<italic>Parameters</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>C group</italic>
<break/>
<italic>n</italic> = 23</th><th align="center" rowspan="1" colspan="1">
<italic>UT group</italic>
<break/>
<italic>n</italic> = 20</th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">
<sup>
a</sup>States T</td><td align="center" rowspan="1" colspan="1">T1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1">T2</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1">T3</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="center" rowspan="1" colspan="1">T4</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">
<sup>
a</sup>States N</td><td align="center" rowspan="1" colspan="1">N0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1">N1</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">8</td></tr><tr><td align="center" rowspan="1" colspan="1">N2</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="2" colspan="1">
<sup>
a</sup>States M</td><td align="center" rowspan="1" colspan="1">M0</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="center" rowspan="1" colspan="1">M1</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">&#x0003c;50</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1">51&#x02013;65</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="center" rowspan="1" colspan="1">66&#x02013;80</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="2" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="center" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="3" colspan="1">Smoke</td><td align="center" rowspan="1" colspan="1">Smokers</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">ex-smokers</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="center" rowspan="1" colspan="1">no smokers</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="5" colspan="1">Associated chronic diseases</td><td align="center" rowspan="1" colspan="1">Without</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">4</td></tr><tr><td align="center" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td align="center" rowspan="1" colspan="1">Hypertension + coronary diseases/dyslipidemia/diabetes</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">7</td></tr><tr><td align="center" rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1">Others</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>
a</sup>Stage of disease currently described by TNM, as published by the American Joint Committee on Cancer (AJCC) and American Cancer Society (ACS).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Evaluation of hemoglobin, and erythrocyte indices of the CRC patients, during six cycles of adjuvant/palliative chemotherapy, without <italic>Uncaria tomentosa </italic>supply (C group) or receiving 300&#x02009;mg/day of <italic>Uncaria tomentosa</italic> (UT group).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">
<italic>Parameters</italic>
</th><th align="center" rowspan="2" colspan="1">
<italic>Group</italic>
</th><th align="center" colspan="7" rowspan="1">
<italic>Chemotherapy cycle</italic>
</th></tr><tr><th align="center" rowspan="1" colspan="1">0</th><th align="center" rowspan="1" colspan="1">1</th><th align="center" rowspan="1" colspan="1">2</th><th align="center" rowspan="1" colspan="1">3</th><th align="center" rowspan="1" colspan="1">4</th><th align="center" rowspan="1" colspan="1">5</th><th align="center" rowspan="1" colspan="1">6</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hb</td><td align="center" rowspan="1" colspan="1">UT</td><td align="center" rowspan="1" colspan="1">123.5</td><td align="center" rowspan="1" colspan="1">125.2</td><td align="center" rowspan="1" colspan="1">127.2</td><td align="center" rowspan="1" colspan="1">123.5</td><td align="center" rowspan="1" colspan="1">125.3</td><td align="center" rowspan="1" colspan="1">121.4</td><td align="center" rowspan="1" colspan="1">118.6</td></tr><tr><td align="left" rowspan="1" colspan="1">g/L</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(14.9)</td><td align="center" rowspan="1" colspan="1">(17.9)</td><td align="center" rowspan="1" colspan="1">(17.0)</td><td align="center" rowspan="1" colspan="1">(14.2)</td><td align="center" rowspan="1" colspan="1">(13.9)</td><td align="center" rowspan="1" colspan="1">(11.1)</td><td align="center" rowspan="1" colspan="1">(10.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">113.7</td><td align="center" rowspan="1" colspan="1">115.1</td><td align="center" rowspan="1" colspan="1">113.3</td><td align="center" rowspan="1" colspan="1">113.9</td><td align="center" rowspan="1" colspan="1">114.9</td><td align="center" rowspan="1" colspan="1">117.0</td><td align="center" rowspan="1" colspan="1">113.7</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(17.6)</td><td align="center" rowspan="1" colspan="1">(13.8)</td><td align="center" rowspan="1" colspan="1">(15.7)</td><td align="center" rowspan="1" colspan="1">(17.2)</td><td align="center" rowspan="1" colspan="1">(14.2)</td><td align="center" rowspan="1" colspan="1">(12.5)</td><td align="center" rowspan="1" colspan="1">(14.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">MCH</td><td align="center" rowspan="1" colspan="1">UT</td><td align="center" rowspan="1" colspan="1">27.53</td><td align="center" rowspan="1" colspan="1">27.88</td><td align="center" rowspan="1" colspan="1">28.37</td><td align="center" rowspan="1" colspan="1">28.95</td><td align="center" rowspan="1" colspan="1">29.66</td><td align="center" rowspan="1" colspan="1">29.69</td><td align="center" rowspan="1" colspan="1">30.60*</td></tr><tr><td align="left" rowspan="1" colspan="1">pg</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(1.99)</td><td align="center" rowspan="1" colspan="1">(1.69)</td><td align="center" rowspan="1" colspan="1">(1.97)</td><td align="center" rowspan="1" colspan="1">(2.20)</td><td align="center" rowspan="1" colspan="1">(2.31)</td><td align="center" rowspan="1" colspan="1">(1.92)</td><td align="center" rowspan="1" colspan="1">(2.16)</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">26.62</td><td align="center" rowspan="1" colspan="1">27.02</td><td align="center" rowspan="1" colspan="1">27.37</td><td align="center" rowspan="1" colspan="1">27.70</td><td align="center" rowspan="1" colspan="1">27.93</td><td align="center" rowspan="1" colspan="1">28.80</td><td align="center" rowspan="1" colspan="1">29.19*</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(2.61)</td><td align="center" rowspan="1" colspan="1">(2.63)</td><td align="center" rowspan="1" colspan="1">(2.59)</td><td align="center" rowspan="1" colspan="1">(2.67)</td><td align="center" rowspan="1" colspan="1">(2.63)</td><td align="center" rowspan="1" colspan="1">(2.60)</td><td align="center" rowspan="1" colspan="1">(2.44)</td></tr><tr><td align="left" rowspan="1" colspan="1">MCV</td><td align="center" rowspan="1" colspan="1">UT</td><td align="center" rowspan="1" colspan="1">84.62</td><td align="center" rowspan="1" colspan="1">85.31</td><td align="center" rowspan="1" colspan="1">86.03</td><td align="center" rowspan="1" colspan="1">87.57</td><td align="center" rowspan="1" colspan="1">89.13</td><td align="center" rowspan="1" colspan="1">90.00</td><td align="center" rowspan="1" colspan="1">91.50**</td></tr><tr><td align="left" rowspan="1" colspan="1">fL</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(4.31)</td><td align="center" rowspan="1" colspan="1">(3.91)</td><td align="center" rowspan="1" colspan="1">(3.65)</td><td align="center" rowspan="1" colspan="1">(5.36)</td><td align="center" rowspan="1" colspan="1">(5.59)</td><td align="center" rowspan="1" colspan="1">(4.90)</td><td align="center" rowspan="1" colspan="1">(4.84)</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">81.94</td><td align="center" rowspan="1" colspan="1">82.53</td><td align="center" rowspan="1" colspan="1">83.74</td><td align="center" rowspan="1" colspan="1">85.28</td><td align="center" rowspan="1" colspan="1">86.27</td><td align="center" rowspan="1" colspan="1">88.29</td><td align="center" rowspan="1" colspan="1">89.22**</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(6.8)</td><td align="center" rowspan="1" colspan="1">(6.58)</td><td align="center" rowspan="1" colspan="1">(6.4)</td><td align="center" rowspan="1" colspan="1">(6.34)</td><td align="center" rowspan="1" colspan="1">(6.02)</td><td align="center" rowspan="1" colspan="1">(5.92)</td><td align="center" rowspan="1" colspan="1">(5.51)</td></tr></tbody></table><table-wrap-foot><fn><p>Values expressed as mean (SD). Hb: hemoglobin, MCH: mean corpuscular hemoglobin, MCV: mean corpuscular volume. UT group: patients treated with FOLFOX4 + <italic>Uncaria tomentosa</italic> 300&#x02009;mg/day (<italic>n</italic> = 20), C group: patients treated with FOLFOX4 (<italic>n</italic> = 23); *<italic>P</italic> &#x0003c; 0.05; **<italic>P</italic> &#x0003c; 0.001; ***<italic>P</italic> &#x0003c; 0.0001 in relation to the day 0.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p>White blood cells count and platelets's evaluation of the CRC patients in adjuvant/palliative chemotherapy, without <italic>Uncaria tomentosa </italic>supply (C group) or receiving 300&#x02009;mg/day of <italic>Uncaria tomentosa</italic> (UT group).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">
<italic>Parameters</italic>
</th><th align="center" rowspan="2" colspan="1">
<italic>Groups</italic>
</th><th align="center" colspan="7" rowspan="1">
<italic>Chemotherapy cycles</italic>
</th></tr><tr><th align="center" rowspan="1" colspan="1">0</th><th align="center" rowspan="1" colspan="1">1</th><th align="center" rowspan="1" colspan="1">2</th><th align="center" rowspan="1" colspan="1">3</th><th align="center" rowspan="1" colspan="1">4</th><th align="center" rowspan="1" colspan="1">5</th><th align="center" rowspan="1" colspan="1">6</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">WBC</td><td align="center" rowspan="1" colspan="1">UT</td><td align="center" rowspan="1" colspan="1">8.178</td><td align="center" rowspan="1" colspan="1">5.689*</td><td align="center" rowspan="1" colspan="1">5.184**</td><td align="center" rowspan="1" colspan="1">4.778**</td><td align="center" rowspan="1" colspan="1">4.956**</td><td align="center" rowspan="1" colspan="1">4.660**</td><td align="center" rowspan="1" colspan="1">4.442**</td></tr><tr><td align="left" rowspan="1" colspan="1">cells &#x000d7;10<sup>9</sup>/L</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(2.705)</td><td align="center" rowspan="1" colspan="1">(1.919)</td><td align="center" rowspan="1" colspan="1">(2.051)</td><td align="center" rowspan="1" colspan="1">(2.022)</td><td align="center" rowspan="1" colspan="1">(2.006)</td><td align="center" rowspan="1" colspan="1">(2.095)</td><td align="center" rowspan="1" colspan="1">(2.433)</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">7.668</td><td align="center" rowspan="1" colspan="1">5.933*</td><td align="center" rowspan="1" colspan="1">5.391*</td><td align="center" rowspan="1" colspan="1">4.886*</td><td align="center" rowspan="1" colspan="1">4.473***</td><td align="center" rowspan="1" colspan="1">4.962**</td><td align="center" rowspan="1" colspan="1">4.195***</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(2.892)</td><td align="center" rowspan="1" colspan="1">(2.137)</td><td align="center" rowspan="1" colspan="1">(2.451)</td><td align="center" rowspan="1" colspan="1">(2.039)</td><td align="center" rowspan="1" colspan="1">(2.086)</td><td align="center" rowspan="1" colspan="1">(2.157)</td><td align="center" rowspan="1" colspan="1">(1.558)</td></tr><tr><td align="left" rowspan="1" colspan="1">Neutrophils</td><td align="center" rowspan="1" colspan="1">UT</td><td align="center" rowspan="1" colspan="1">5.345</td><td align="center" rowspan="1" colspan="1">3.069*</td><td align="center" rowspan="1" colspan="1">2.600**</td><td align="center" rowspan="1" colspan="1">2.441**</td><td align="center" rowspan="1" colspan="1">2.429**</td><td align="center" rowspan="1" colspan="1">2.227**</td><td align="center" rowspan="1" colspan="1">2.343***</td></tr><tr><td align="left" rowspan="1" colspan="1">cells &#x000d7;10<sup>9</sup>/L</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(2.691)</td><td align="center" rowspan="1" colspan="1">(1.455)</td><td align="center" rowspan="1" colspan="1">(1.411)</td><td align="center" rowspan="1" colspan="1">(1.401)</td><td align="center" rowspan="1" colspan="1">(1.456)</td><td align="center" rowspan="1" colspan="1">(1.506)</td><td align="center" rowspan="1" colspan="1">(1.842)</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">4.871</td><td align="center" rowspan="1" colspan="1">3.285*</td><td align="center" rowspan="1" colspan="1">2.848**</td><td align="center" rowspan="1" colspan="1">2.295***</td><td align="center" rowspan="1" colspan="1">2.190***</td><td align="center" rowspan="1" colspan="1">2.514*</td><td align="center" rowspan="1" colspan="1">1.975***</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(2.674)</td><td align="center" rowspan="1" colspan="1">(1.618)</td><td align="center" rowspan="1" colspan="1">(1.858)</td><td align="center" rowspan="1" colspan="1">(2.295)</td><td align="center" rowspan="1" colspan="1">(1.628)</td><td align="center" rowspan="1" colspan="1">(1.797)</td><td align="center" rowspan="1" colspan="1">(1.186)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphocytes</td><td align="center" rowspan="1" colspan="1">UT</td><td align="center" rowspan="1" colspan="1">2.038</td><td align="center" rowspan="1" colspan="1">1.888</td><td align="center" rowspan="1" colspan="1">1.859</td><td align="center" rowspan="1" colspan="1">1.673</td><td align="center" rowspan="1" colspan="1">1.776</td><td align="center" rowspan="1" colspan="1">1.728</td><td align="center" rowspan="1" colspan="1">1.433*</td></tr><tr><td align="left" rowspan="1" colspan="1">cells &#x000d7;10<sup>9</sup>/L</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(.735)</td><td align="center" rowspan="1" colspan="1">(.681)</td><td align="center" rowspan="1" colspan="1">(.656)</td><td align="center" rowspan="1" colspan="1">(.642)</td><td align="center" rowspan="1" colspan="1">(.661)</td><td align="center" rowspan="1" colspan="1">(.754)</td><td align="center" rowspan="1" colspan="1">(.504)</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">1.901</td><td align="center" rowspan="1" colspan="1">1.888</td><td align="center" rowspan="1" colspan="1">1.815</td><td align="center" rowspan="1" colspan="1">1.769</td><td align="center" rowspan="1" colspan="1">1.650</td><td align="center" rowspan="1" colspan="1">1.697</td><td align="center" rowspan="1" colspan="1">1.578</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(.702)</td><td align="center" rowspan="1" colspan="1">(.737)</td><td align="center" rowspan="1" colspan="1">(.717)</td><td align="center" rowspan="1" colspan="1">(.827)</td><td align="center" rowspan="1" colspan="1">(.648)</td><td align="center" rowspan="1" colspan="1">(.531)</td><td align="center" rowspan="1" colspan="1">(.659)</td></tr><tr><td align="left" rowspan="1" colspan="1">Monocytes</td><td align="center" rowspan="1" colspan="1">UT</td><td align="center" rowspan="1" colspan="1">.538</td><td align="center" rowspan="1" colspan="1">.515</td><td align="center" rowspan="1" colspan="1">.528</td><td align="center" rowspan="1" colspan="1">.482</td><td align="center" rowspan="1" colspan="1">.546</td><td align="center" rowspan="1" colspan="1">.547</td><td align="center" rowspan="1" colspan="1">.542</td></tr><tr><td align="left" rowspan="1" colspan="1">cells &#x000d7;10<sup>9</sup>/L</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(.215)</td><td align="center" rowspan="1" colspan="1">(.157)</td><td align="center" rowspan="1" colspan="1">(.197)</td><td align="center" rowspan="1" colspan="1">(.216)</td><td align="center" rowspan="1" colspan="1">(.244)</td><td align="center" rowspan="1" colspan="1">(.241)</td><td align="center" rowspan="1" colspan="1">(.306)</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">.542</td><td align="center" rowspan="1" colspan="1">.533</td><td align="center" rowspan="1" colspan="1">.570</td><td align="center" rowspan="1" colspan="1">.602</td><td align="center" rowspan="1" colspan="1">.470</td><td align="center" rowspan="1" colspan="1">.595</td><td align="center" rowspan="1" colspan="1">.498</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(.245)</td><td align="center" rowspan="1" colspan="1">(.254)</td><td align="center" rowspan="1" colspan="1">(.254)</td><td align="center" rowspan="1" colspan="1">(.272)</td><td align="center" rowspan="1" colspan="1">(.197)</td><td align="center" rowspan="1" colspan="1">(.262)</td><td align="center" rowspan="1" colspan="1">(.231)</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelets</td><td align="center" rowspan="1" colspan="1">UT</td><td align="center" rowspan="1" colspan="1">263</td><td align="center" rowspan="1" colspan="1">188*</td><td align="center" rowspan="1" colspan="1">174*</td><td align="center" rowspan="1" colspan="1">146***</td><td align="center" rowspan="1" colspan="1">135***</td><td align="center" rowspan="1" colspan="1">117***</td><td align="center" rowspan="1" colspan="1">117***</td></tr><tr><td align="left" rowspan="1" colspan="1">count &#x000d7;10<sup>9</sup>/L</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(92)</td><td align="center" rowspan="1" colspan="1">(43)</td><td align="center" rowspan="1" colspan="1">(55)</td><td align="center" rowspan="1" colspan="1">(48)</td><td align="center" rowspan="1" colspan="1">(51)</td><td align="center" rowspan="1" colspan="1">(42 )</td><td align="center" rowspan="1" colspan="1">(33)</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">286</td><td align="center" rowspan="1" colspan="1">216*</td><td align="center" rowspan="1" colspan="1">197**</td><td align="center" rowspan="1" colspan="1">161***</td><td align="center" rowspan="1" colspan="1">149***</td><td align="center" rowspan="1" colspan="1">165***</td><td align="center" rowspan="1" colspan="1">141***</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(76)</td><td align="center" rowspan="1" colspan="1">(68)</td><td align="center" rowspan="1" colspan="1">(64)</td><td align="center" rowspan="1" colspan="1">(70 )</td><td align="center" rowspan="1" colspan="1">(66)</td><td align="center" rowspan="1" colspan="1">(57)</td><td align="center" rowspan="1" colspan="1">(58)</td></tr></tbody></table><table-wrap-foot><fn><p>Values expressed as mean (SD). UT group: patients treated with FOLFOX4 + <italic>Uncaria tomentosa</italic> 300&#x02009;mg/daily (<italic>n</italic> = 20); C group: CRC patients received FOLFOX4 (<italic>n</italic> = 23); *<italic>P</italic> &#x0003c; 0.05; **<italic>P</italic> &#x0003c; 0.001; ***<italic>P</italic> &#x0003c; 0.0001 in relation to the day 0.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" position="float"><label>Table 4</label><caption><p>Evaluation of lipid peroxidation, carbonylation of serum protein, DNA damage and antioxidant defenses of the CRC patients in adjuvant/palliative chemotherapy (FOLFOX4), without <italic>Uncaria tomentosa </italic>supply (C group) or receiving 300&#x02009;mg/day of <italic>Uncaria tomentosa</italic> (UT group).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">
<italic>Parameters</italic>
</th><th align="center" rowspan="2" colspan="1">
<italic>Group</italic>
</th><th align="center" colspan="7" rowspan="1">
<italic>Chemotherapy cycles</italic>
</th></tr><tr><th align="center" rowspan="1" colspan="1">0</th><th align="center" rowspan="1" colspan="1">1</th><th align="center" rowspan="1" colspan="1">2</th><th align="center" rowspan="1" colspan="1">3</th><th align="center" rowspan="1" colspan="1">4</th><th align="center" rowspan="1" colspan="1">5</th><th align="center" rowspan="1" colspan="1">6</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">TBARS nmol</td><td align="center" rowspan="1" colspan="1">UT</td><td align="center" rowspan="1" colspan="1">16.7</td><td align="center" rowspan="1" colspan="1">16.2</td><td align="center" rowspan="1" colspan="1">18.3</td><td align="center" rowspan="1" colspan="1">17.9</td><td align="center" rowspan="1" colspan="1">17.7</td><td align="center" rowspan="1" colspan="1">17.8</td><td align="center" rowspan="1" colspan="1">21.6</td></tr><tr><td align="left" rowspan="1" colspan="1">MDA/mL</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(9.34)</td><td align="center" rowspan="1" colspan="1">(7.1)</td><td align="center" rowspan="1" colspan="1">(7.2)</td><td align="center" rowspan="1" colspan="1">(6.9)</td><td align="center" rowspan="1" colspan="1">(4.1)</td><td align="center" rowspan="1" colspan="1">(3.4)</td><td align="center" rowspan="1" colspan="1">(11.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">22.5</td><td align="center" rowspan="1" colspan="1">18.8</td><td align="center" rowspan="1" colspan="1">17.8</td><td align="center" rowspan="1" colspan="1">19.4</td><td align="center" rowspan="1" colspan="1">21.2</td><td align="center" rowspan="1" colspan="1">22.4</td><td align="center" rowspan="1" colspan="1">22.9</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(11.6)</td><td align="center" rowspan="1" colspan="1">(10.9)</td><td align="center" rowspan="1" colspan="1">(11.3)</td><td align="center" rowspan="1" colspan="1">(10.5)</td><td align="center" rowspan="1" colspan="1">(8.9)</td><td align="center" rowspan="1" colspan="1">(9.7)</td><td align="center" rowspan="1" colspan="1">(10.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein carbonyl</td><td align="center" rowspan="1" colspan="1">UT</td><td align="center" rowspan="1" colspan="1">0.63</td><td align="center" rowspan="1" colspan="1">0.56</td><td align="center" rowspan="1" colspan="1">0.61</td><td align="center" rowspan="1" colspan="1">0.61</td><td align="center" rowspan="1" colspan="1">0.68</td><td align="center" rowspan="1" colspan="1">0.67</td><td align="center" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">nmol/mg protein</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(0.2)</td><td align="center" rowspan="1" colspan="1">(0.2)</td><td align="center" rowspan="1" colspan="1">(0.17)</td><td align="center" rowspan="1" colspan="1">(0.18)</td><td align="center" rowspan="1" colspan="1">(0.26)</td><td align="center" rowspan="1" colspan="1">(0.2)</td><td align="center" rowspan="1" colspan="1">(0.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">0.79</td><td align="center" rowspan="1" colspan="1">0.77</td><td align="center" rowspan="1" colspan="1">0.73</td><td align="center" rowspan="1" colspan="1">0.72</td><td align="center" rowspan="1" colspan="1">0.78</td><td align="center" rowspan="1" colspan="1">0.9</td><td align="center" rowspan="1" colspan="1">0.84</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(0.37)</td><td align="center" rowspan="1" colspan="1">(0.4)</td><td align="center" rowspan="1" colspan="1">(0.39)</td><td align="center" rowspan="1" colspan="1">(0.36)</td><td align="center" rowspan="1" colspan="1">(0.37)</td><td align="center" rowspan="1" colspan="1">(0.43)</td><td align="center" rowspan="1" colspan="1">(0.37)</td></tr><tr><td align="left" rowspan="1" colspan="1">Comet assay</td><td align="center" rowspan="1" colspan="1">UT</td><td align="center" rowspan="1" colspan="1">29.04</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">26.78</td></tr><tr><td align="left" rowspan="1" colspan="1">Index damage</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(34.18)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(31.99)</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">26.94</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">34.66</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(49.3)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(46.63)</td></tr><tr><td align="left" rowspan="1" colspan="1">Catalase</td><td align="center" rowspan="1" colspan="1">UT</td><td align="center" rowspan="1" colspan="1">7.85</td><td align="center" rowspan="1" colspan="1">8.2</td><td align="center" rowspan="1" colspan="1">7.65</td><td align="center" rowspan="1" colspan="1">9.12</td><td align="center" rowspan="1" colspan="1">8.97</td><td align="center" rowspan="1" colspan="1">9.33</td><td align="center" rowspan="1" colspan="1">10.39</td></tr><tr><td align="left" rowspan="1" colspan="1">pmol/mg protein</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(3.3)</td><td align="center" rowspan="1" colspan="1">(3.0)</td><td align="center" rowspan="1" colspan="1">(2.81)</td><td align="center" rowspan="1" colspan="1">(4.75)</td><td align="center" rowspan="1" colspan="1">(4.71)</td><td align="center" rowspan="1" colspan="1">(3.27)</td><td align="center" rowspan="1" colspan="1">(4.08)</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">9.05</td><td align="center" rowspan="1" colspan="1">8.29</td><td align="center" rowspan="1" colspan="1">8.51</td><td align="center" rowspan="1" colspan="1">8.06</td><td align="center" rowspan="1" colspan="1">9.07</td><td align="center" rowspan="1" colspan="1">8.31</td><td align="center" rowspan="1" colspan="1">9.38</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(4.9)</td><td align="center" rowspan="1" colspan="1">(2.7)</td><td align="center" rowspan="1" colspan="1">(4.05)</td><td align="center" rowspan="1" colspan="1">(3.51)</td><td align="center" rowspan="1" colspan="1">(3.71)</td><td align="center" rowspan="1" colspan="1">(3.07)</td><td align="center" rowspan="1" colspan="1">(3.78)</td></tr><tr><td align="left" rowspan="1" colspan="1">SOD</td><td align="center" rowspan="1" colspan="1">UT</td><td align="center" rowspan="1" colspan="1">1.82</td><td align="center" rowspan="1" colspan="1">1.85</td><td align="center" rowspan="1" colspan="1">1.95</td><td align="center" rowspan="1" colspan="1">2.19</td><td align="center" rowspan="1" colspan="1">1.95</td><td align="center" rowspan="1" colspan="1">2.29*</td><td align="center" rowspan="1" colspan="1">2.41*</td></tr><tr><td align="left" rowspan="1" colspan="1">U/mg protein</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(0.5)</td><td align="center" rowspan="1" colspan="1">(0.44)</td><td align="center" rowspan="1" colspan="1">(0.44)</td><td align="center" rowspan="1" colspan="1">(0.43)</td><td align="center" rowspan="1" colspan="1">(0.43)</td><td align="center" rowspan="1" colspan="1">(0.44)</td><td align="center" rowspan="1" colspan="1">(0.56)</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">1.91</td><td align="center" rowspan="1" colspan="1">1.91</td><td align="center" rowspan="1" colspan="1">2.1</td><td align="center" rowspan="1" colspan="1">2.15</td><td align="center" rowspan="1" colspan="1">2.09</td><td align="center" rowspan="1" colspan="1">2.12</td><td align="center" rowspan="1" colspan="1">2.13</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">(0.8)</td><td align="center" rowspan="1" colspan="1">(0.76)</td><td align="center" rowspan="1" colspan="1">(0.71)</td><td align="center" rowspan="1" colspan="1">(0.78)</td><td align="center" rowspan="1" colspan="1">(0.7)</td><td align="center" rowspan="1" colspan="1">(0.81)</td><td align="center" rowspan="1" colspan="1">(0.72)</td></tr></tbody></table><table-wrap-foot><fn><p>Data expressed in mean (SD). TBARS, thiobarbituric acid-reactive substances; SOD, superoxide dismutase; UT group: patients treated with FOLFOX4 + <italic>Uncaria tomentosa</italic> 300&#x02009;mg/daily (<italic>n</italic> = 20); C group: CRC patients received FOLFOX4 (<italic>n</italic> = 23). *<italic>P</italic> &#x0003c; 0.05 in relation to the day 0.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab5" position="float"><label>Table 5</label><caption><p>Immune status of CRC patients before treatment began and after 6 cycles of adjuvant/palliative chemotherapy (FOLFOX4) without <italic>Uncaria tomentosa </italic>supply (C group) or receiving 300&#x02009;mg/day of <italic>Uncaria tomentosa</italic> (UT group).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">
<italic>Parameters</italic>
</th><th align="center" rowspan="2" colspan="1">
<italic>Group</italic>
</th><th align="center" colspan="2" rowspan="1">
<italic>Chemotherapy cycles</italic>
</th></tr><tr><th align="center" rowspan="1" colspan="1">0</th><th align="center" rowspan="1" colspan="1">6</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CD4<sup>+</sup> T Cells</td><td align="center" rowspan="1" colspan="1">UT</td><td align="center" rowspan="1" colspan="1">958.36 (414.6)</td><td align="center" rowspan="1" colspan="1">720.28 (271.72)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cells/<italic>&#x003bc;</italic>L</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">828.45 (431.25)</td><td align="center" rowspan="1" colspan="1">848.38 (430.56)</td></tr><tr><td align="left" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">CD8<sup>+</sup> T cells</td><td align="center" rowspan="1" colspan="1">UT</td><td align="center" rowspan="1" colspan="1">494.0 (231.28)</td><td align="center" rowspan="1" colspan="1">390.64 (223.62)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cells/<italic>&#x003bc;</italic>L</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">490.29 (271.14)</td><td align="center" rowspan="1" colspan="1">394.27 (149.96)</td></tr><tr><td align="left" rowspan="2" colspan="1">CD4<sup>+</sup> T/CD8<sup>+</sup> T Ratio</td><td align="center" rowspan="1" colspan="1">UT</td><td align="center" rowspan="1" colspan="1">2.17 (0.76)</td><td align="center" rowspan="1" colspan="1">2.21 (0.78)</td></tr><tr><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">1.96 (1.03)</td><td align="center" rowspan="1" colspan="1">2.30 (1.08)</td></tr><tr><td align="left" rowspan="1" colspan="1">IL6</td><td align="center" rowspan="1" colspan="1">UT</td><td align="center" rowspan="1" colspan="1">4.07<sup>#</sup> (6.54)</td><td align="center" rowspan="1" colspan="1">5.1<sup>#</sup> (6.12)</td></tr><tr><td align="left" rowspan="1" colspan="1">ng/mL</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">12.97 (13.28)</td><td align="center" rowspan="1" colspan="1">16.66 (18.2)</td></tr></tbody></table><table-wrap-foot><fn><p>Data expressed as mean (SD); UT group: patients treated with FOLFOX4 + <italic>Uncaria tomentosa</italic> 300&#x02009;mg/daily (<italic>n</italic> = 20); C group: CRC patients received FOLFOX4 (<italic>n</italic> = 23). <sup>#</sup>
<italic>P</italic> &#x0003c; 0.05 between groups.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab6" position="float"><label>Table 6</label><caption><p>Frequency of side effects reported by CRC patients in adjuvant/palliative chemotherapy in interview at first and sixth cycle of the treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">
</th><th align="center" colspan="5" rowspan="1">
<italic>After 1 chemotherapy cycle</italic>
</th><th align="center" colspan="5" rowspan="1">
<italic>After 6 chemotherapy cycles</italic>
</th></tr><tr><th align="left" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">Not present</th><th align="center" rowspan="1" colspan="1">rarely</th><th align="center" rowspan="1" colspan="1">sometimes</th><th align="center" rowspan="1" colspan="1">often</th><th align="center" rowspan="1" colspan="1">Always</th><th align="center" rowspan="1" colspan="1">Not present</th><th align="center" rowspan="1" colspan="1">Rarely</th><th align="center" rowspan="1" colspan="1">Sometimes</th><th align="center" rowspan="1" colspan="1">Often</th><th align="center" rowspan="1" colspan="1">always</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Fatigue</td><td align="center" rowspan="1" colspan="1">60.5</td><td align="center" rowspan="1" colspan="1">13.2</td><td align="center" rowspan="1" colspan="1">13.2</td><td align="center" rowspan="1" colspan="1">5.3</td><td align="center" rowspan="1" colspan="1">7.9</td><td align="center" rowspan="1" colspan="1">54.3</td><td align="center" rowspan="1" colspan="1">5.7</td><td align="center" rowspan="1" colspan="1">22.9</td><td align="center" rowspan="1" colspan="1">5.7</td><td align="center" rowspan="1" colspan="1">11.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Insomnia</td><td align="center" rowspan="1" colspan="1">86.8</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">7.9</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">97.1</td><td align="center" rowspan="1" colspan="1">2.9</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Vomiting</td><td align="center" rowspan="1" colspan="1">78.9</td><td align="center" rowspan="1" colspan="1">10.5</td><td align="center" rowspan="1" colspan="1">10.5</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">nausea</td><td align="center" rowspan="1" colspan="1">60.5</td><td align="center" rowspan="1" colspan="1">15.8</td><td align="center" rowspan="1" colspan="1">21.1</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">80.0</td><td align="center" rowspan="1" colspan="1">15.0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">5.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Dry skin</td><td align="center" rowspan="1" colspan="1">91.2</td><td align="center" rowspan="1" colspan="1">2.9</td><td align="center" rowspan="1" colspan="1">2.9</td><td align="center" rowspan="1" colspan="1">2.9</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">88.6</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">5.7</td><td align="center" rowspan="1" colspan="1">5.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Pruritus/itching</td><td align="center" rowspan="1" colspan="1">81.6</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">10.5</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">5.3</td><td align="center" rowspan="1" colspan="1">91.4</td><td align="center" rowspan="1" colspan="1">5.7</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Fever</td><td align="center" rowspan="1" colspan="1">97.4</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">97.1</td><td align="center" rowspan="1" colspan="1">2.9</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn><p>Data expressed as % of the patients who had symptoms.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab7" position="float"><label>Table 7</label><caption><p>Adverse events observed in CRC patients in adjuvant/palliative chemotherapy with FOLFOX4 (<italic>n</italic> = 43).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">
</th><th align="center" colspan="5" rowspan="1">
<italic>After 1 chemotherapy cycle (FOLFOX4)</italic>
</th><th align="center" colspan="5" rowspan="1">
<italic>After 6 chemotherapy cycles (FOLFOX4)</italic>
</th></tr><tr><th align="left" rowspan="1" colspan="1">
</th><th align="center" colspan="5" rowspan="1">Grade refers to the severity of the AE*</th><th align="center" colspan="5" rowspan="1">Grade refers to the severity of the AE</th></tr><tr><th align="left" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">0</th><th align="center" rowspan="1" colspan="1">1</th><th align="center" rowspan="1" colspan="1">2</th><th align="center" rowspan="1" colspan="1">3</th><th align="center" rowspan="1" colspan="1">4</th><th align="center" rowspan="1" colspan="1">0</th><th align="center" rowspan="1" colspan="1">1</th><th align="center" rowspan="1" colspan="1">2</th><th align="center" rowspan="1" colspan="1">3</th><th align="center" rowspan="1" colspan="1">4</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hemoglobin</td><td align="center" rowspan="1" colspan="1">82.9</td><td align="center" rowspan="1" colspan="1">12.2</td><td align="center" rowspan="1" colspan="1">4.9</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">76.9</td><td align="center" rowspan="1" colspan="1">17.9</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Leukocytes (total WBC)</td><td align="center" rowspan="1" colspan="1">97.6</td><td align="center" rowspan="1" colspan="1">2.4</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">74.4</td><td align="center" rowspan="1" colspan="1">5.1</td><td align="center" rowspan="1" colspan="1">15.4</td><td align="center" rowspan="1" colspan="1">5.1</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Neutrophils/granulocytes</td><td align="center" rowspan="1" colspan="1">85.4</td><td align="center" rowspan="1" colspan="1">7.3</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">4.9</td><td align="center" rowspan="1" colspan="1">2.4</td><td align="center" rowspan="1" colspan="1">48.7</td><td align="center" rowspan="1" colspan="1">12.8</td><td align="center" rowspan="1" colspan="1">10.3</td><td align="center" rowspan="1" colspan="1">17.9</td><td align="center" rowspan="1" colspan="1">7.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphocytes</td><td align="center" rowspan="1" colspan="1">95.1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">4.9</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">92.3</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">7.7</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelets</td><td align="center" rowspan="1" colspan="1">97.6</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2.4</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">84.6</td><td align="center" rowspan="1" colspan="1">10.3</td><td align="center" rowspan="1" colspan="1">5.1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight loss</td><td align="center" rowspan="1" colspan="1">82.9</td><td align="center" rowspan="1" colspan="1">9.8</td><td align="center" rowspan="1" colspan="1">2.4</td><td align="center" rowspan="1" colspan="1">4.9</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">92.3</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">5.1</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Hyperglycemia</td><td align="center" rowspan="1" colspan="1">97.6</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2.4</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">87.2</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">7.7</td><td align="center" rowspan="1" colspan="1">5.1</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x003b3;</italic>-glutamyl transpeptidase</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">89.8</td><td align="center" rowspan="1" colspan="1">10.2</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Alkaline phosphatase</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">84.6</td><td align="center" rowspan="1" colspan="1">15.4</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Neuropathy: sensory</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">94,9</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">5.1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Infection with Grade 3 or 4 neutrophils</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">97.4</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Diarrhea</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">92.3</td><td align="center" rowspan="1" colspan="1">x</td><td align="center" rowspan="1" colspan="1">7.7</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn><p>Values expressed as % of the patients who had AE. *Grade refers to the severity of the AE: grade 1 = mild AE; grade 2 = moderate AE; grade 3 = severe AE; grade 4 = life-threatening or disabling AE; grade 5 = death related to an AE [<xref rid="B22" ref-type="bibr">22</xref>].</p></fn></table-wrap-foot></table-wrap></floats-group></article>